自1890年Behring发现抗体以来,免疫学家为获得单特异的抗体作了许多努力,但都没有成功。本世纪七十年代,细胞融合技术的发展及其向免疫学的渗透,却产生了意想不到的巨大成功。由于利用淋巴细胞杂交瘤技术可以持续地获得几乎针对任何抗原决定基的单克隆抗体,所以自1975年Kohler和Milstein首次建立这项技术以来,淋巴细胞杂交瘤技术取得了迅速进展。目前,产生多种特异的单克隆抗体的杂交瘤株已经建立。除B淋巴细胞杂交瘤外,具有多种T细 Since the discovery of antibodies by Behring in 1890, immunologists have made many efforts to obtain monospecific antibodies, but none have succeeded. In the seventies of this century, the development of cell fusion technology and its infiltration into immunology have produced unexpectedly great success. Due to the continuous availability of monoclonal antibodies against virtually any epitope by lymphocyte hybridoma technology, rapid advances have been made in lymphocyte hybridoma technology since Kohler and Milstein first established this technology in 1975. Currently, hybridomas producing multiple specific monoclonal antibodies have been established. In addition to B lymphocyte hybridoma, with a variety of T fine